FDA Expands Imbruvica Use for Non-Hodgkin Lymphoma
Imbruvica (ibrutinib) can now be prescribed for patients with Waldenström’s macroglobulinemia (WM), a rare form of cancer that begins in the body’s immune system (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 4, 2015 Category: Pharmaceuticals Source Type: news

Roche says study of lymphoma drug shows significant benefit
ZURICH (Reuters) - Swiss drugmaker Roche said on Wednesday a late-stage study of its treatment for slow-growing, or indolent, non-Hodgkin's lymphoma showed significant benefit and met its primary endpoint early. (Source: Reuters: Health)
Source: Reuters: Health - February 4, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

FDA expands approved use of Imbruvica for rare form of non-Hodgkin lymphoma
The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for previously treated patients with Waldenström’s macroglobulinemia (WM), a rare form of cancer that begins in the body’s immune system. The drug received a breakthrough therapy designation for this use. (Source: Food and Drug Administration)
Source: Food and Drug Administration - January 29, 2015 Category: American Health Source Type: news

Hampstead and Westminster men's hockey team in naked calendar for charity
Sixteen of the Hampstead and Westminster Hockey Club men's first team took part in the shoot after a former teammate was diagnosed with non-hodgkin's lymphoma. (Source: the Mail online | Health)
Source: the Mail online | Health - December 30, 2014 Category: Consumer Health News Source Type: news

Entecavir Lowers HBV Reactivation Risk Better Than LamivudineEntecavir Lowers HBV Reactivation Risk Better Than Lamivudine
A new randomized trial has suggested that entecavir is better than lamivudine for preventing HBV reactivation and HBV-related hepatitis in patients with non-Hodgkin lymphoma who are receiving R-CHOP. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 26, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Teen who was 'never ill' now battling cancer and needs a life-saving transplant
Emily Clark, 17, from Cwmbran in Wales, is battling non-hodgkin lymphoma for a second time. Specialists say a transplant is her only hope. (Source: the Mail online | Health)
Source: the Mail online | Health - December 15, 2014 Category: Consumer Health News Source Type: news

5 Life Lessons I Learned From Cancer
According to the American Cancer Society, the statistics are startling. Cancer is claiming more and more lives every day. The numbers tell us that over 1.6 million people will have been diagnosed by the end of 2014 -- a diagnosis that can rock the foundation of anyone's world. In November 1999, that's what it felt like for me and my husband when he was diagnosed with stage IV cancer -- Non-Hodgkin's Lymphoma. At one point, we asked the oncologist what we could do to help support the hospital treatments and aid in the fight against cancer. "Nothing," he said. I'm sure it's not too hard to imagine how devastating...
Source: Healthy Living - The Huffington Post - December 13, 2014 Category: Consumer Health News Source Type: news

North Texas Fracking Zone Sees Growing Health Worries
This story was published by The Center for Public Integrity, a nonprofit, nonpartisan investigative news organization in Washington, D.C. DALLAS—Propped up on a hospital bed, Taylor Ishee listened as his mother shared a conviction that choked her up. His rare cancer had a cause, she believes, and it wasn’t genetics. Others in Texas have drawn the same conclusions about their confounding illnesses. Jana DeGrand, who suffered a heart attack and needed both her gallbladder and her appendix removed. Rebecca Williams, fighting off unexplained rashes, sharp headaches and repeated bouts of pneumonia. Maile Bush, who...
Source: Science - The Huffington Post - December 11, 2014 Category: Science Source Type: news

Glyphosate disrupting root systems, destroying soil nutrients and eliminating earthworms
(NaturalNews) More than 100 million pounds of the weedkiller glyphosate is applied annually to crops in the U.S., contributing to cancers such as non-Hodgkin's lymphoma and liver, pancreas and thyroid cancer, among other health complications. One of the main ingredients in Monsanto's... (Source: NaturalNews.com)
Source: NaturalNews.com - December 10, 2014 Category: Consumer Health News Source Type: news

Cornerstone begins Phase I trial of CPI-613 to treat B-cell non-Hodgkin lymphoma
US-based Cornerstone Pharmaceuticals has started a Phase I clinical trial of its lead Altered Energy Metabolism Directed (AEMD) drug candidate CPI-613 to treat patients with relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL). (Source: Drug Development Technology)
Source: Drug Development Technology - December 8, 2014 Category: Pharmaceuticals Source Type: news

Interim Data From Phase 1 Dose Escalation Clinical Trial of TGR-1202, the Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity and Lack of Hepatic Toxicity in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - December 7, 2014 Category: Pharmaceuticals Source Type: news

Cornerstone Pharmaceuticals Commences Phase I Clinical Trial of CPI-613 for the Treatment of B-Cell Non-Hodgkin Lymphoma
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - December 5, 2014 Category: Pharmaceuticals Source Type: news

New Treatment for Non - Hodgkin Lymphoma Approved
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

FDA Approves Poteligeo for Rare Types of Non - Hodgkin Lymphoma
Drug approved to treat relapsed or refractory mycosis fungoides and Sézary syndrome (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Institutional, Source Type: news

FDA Approves First Biosimilar to Non - Hodgkin ’ s Lymphoma Drug
Truxima approved to treat adults with CD20 - positive, B - cell non - Hodgkin's lymphoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Institutional, Source Type: news

Massive Non-Hodgkin Lymphoma study underway
This study has resulted many published papers and is considered "huge in scale." (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 6, 2014 Category: Science Source Type: news

Hodgkin's vs. non-Hodgkin's lymphoma
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - November 6, 2014 Category: Consumer Health News Source Type: news

Pharmacyclics and Roche to evaluate Imbruvica-Gazyva combination in lymphoma, leukaemia patients
Pharmacyclics and Roche have entered into a clinical drug supply agreement to evaluate the safety, tolerability and preliminary efficacy of Imbruvica (ibrutinib) in combination with Gazyva (obinutuzumab) in patients with non-Hodgkin lymphoma (NHL) an… (Source: Drug Development Technology)
Source: Drug Development Technology - October 17, 2014 Category: Pharmaceuticals Source Type: news

BMS, Pharmacyclics and Janssen partner to evaluate non-Hodgkin's lymphoma drug
Bristol-Myers Squibb (BMS), Pharmacyclics and Janssen Research & Development have collaborated to start a Phase I/II clinical trial to assess the safety, tolerability and preliminary efficacy concerning the combination of OPDIVO (nivolumab) and IMBRU… (Source: Drug Development Technology)
Source: Drug Development Technology - October 14, 2014 Category: Pharmaceuticals Source Type: news

APAC Non-Hodgkin Lymphoma Market to Grow at 6.6% CAGR Through 2020,...
New research report “Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting” elaborated by GBI Research is now...(PRWeb September 26, 2014)Read the full story at http://www.prweb.com/releases/2014/09/prweb12203364.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 27, 2014 Category: Pharmaceuticals Source Type: news

Hodgkin's and Non-Hodgkin's Lymphoma
series:Cancer Treatment and ResearchOver recent years, there has been a dramatic increase in knowledge of the biology of the lymphomas which has been accompanied by the emergence of new treatments that offer both improvements in efficacy and reduction in toxicity. Molecular profiling of tumor tissue and other new advances have led to a better understanding of the genetic basis of lymphoma, identification of new therapeutic ... (Source: Springer Medicine titles)
Source: Springer Medicine titles - September 23, 2014 Category: Databases & Libraries Tags: Oncology Source Type: news

Cutaneous Intravascular Natural Killer-Cell LymphomaCutaneous Intravascular Natural Killer-Cell Lymphoma
This report documents a case of intravascular lymphoma, a rare and aggressive variant of extranodal non-Hodgkin lymphoma. American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 2, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020...
ResearchMoz.us include new market research report" Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020" to its huge collection of research reports.(PRWeb September 01, 2014)Read the full story at http://www.prweb.com/releases/2014/09/prweb12135147.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 1, 2014 Category: Pharmaceuticals Source Type: news

B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion...
MarketOptimizer.org adds “OpportunityAnalyzer: Non-Hodgkin’s B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018” to its store. Overview of B-cell NHL, including epidemiology, etiology,...(PRWeb September 01, 2014)Read the full story at http://www.prweb.com/releases/2018-non-hodgkins-b-cell/lymphoma-market-analysis/prweb12135505.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 1, 2014 Category: Pharmaceuticals Source Type: news

Kite Pharma's Shares Soar After Study Results
Eight patients with aggressive non-Hodgkin's lymphoma treated with Kite Pharma's cancer drug lead candidate were in complete remission and four others in partial remission, the company said Monday. (Source: WSJ.com: Health)
Source: WSJ.com: Health - August 26, 2014 Category: Pharmaceuticals Tags: PAID Source Type: news

Kite Pharma announces positive results in patients with aggressive non-Hodgkin's lymphoma
(Burns McClellan) Kite Pharma Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy products for the treatment of cancer, today announced the publication of clinical results in a cohort of patients demonstrating the potential to treat aggressive non-Hodgkin's lymphoma with an anti-CD19 chimeric antigen receptor T cell therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 25, 2014 Category: Global & Universal Source Type: news

Phase 1 Clinical Trial of Antibody-Drug Conjugate SGN-CD70A for Non-Hodgkin Lymphoma and Renal Cell Carcinoma
"CD70 is a very promising ADC antigen, which is highly expressed in both NHL and RCC, and has minimal expression in healthy tissues," said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development, at Seattle Genetics.08/21/2014 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 21, 2014 Category: Cancer & Oncology Source Type: news

Is UK obesity fuelling an increase in 10 cancers?
Conclusion This large UK cohort study of more than 5 million people has found that, although there was variation in the effect of BMI on different cancers, a higher BMI was associated with increased risk of several cancers. Overall, the researchers estimated that a 1kg/m² population-wide increase in BMI would result in 3,790 additional people in the UK each year developing uterus, gallbladder, kidney, cervix, thyroid, leukaemia, liver, colon, ovarian or postmenopausal breast cancer. However, not all of the identified links were completely clear, with some showing a clearer linear association between increasing BMI an...
Source: NHS News Feed - August 14, 2014 Category: Consumer Health News Tags: Obesity Cancer Source Type: news

Seattle Genetics begins Phase I trial of lymphoma and carcinoma drug SGN-CD70A
Seattle Genetics has initiated a Phase I clinical trial assessing SGN-CD70A for CD70-positive relapsed or refractory non-Hodgkin lymphoma (NHL) and metastatic renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - August 13, 2014 Category: Pharmaceuticals Source Type: news

CTI BioPharma receives Israeli approval for aggressive B-cell non-Hodgkin's lymphoma therapy
CTI BioPharma has obtained Israeli Ministry of Health's approval for Pixuvri (pixantrone), as a monotherapy to treat adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma who have received up to three previous c… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 21, 2014 Category: Pharmaceuticals Source Type: news

FDA Approves Beleodaq for Non-Hodgkin Lymphoma
FDA Approves Beleodaq to Treat Rare, Aggressive Form of Non-Hodgkin Lymphoma (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 8, 2014 Category: Journals (General) Source Type: news

Beleodaq OK'd for Rare Form of NHL
WASHINGTON (MedPage Today) -- The FDA has approved the histone deacetylase inhibitor belinostat for treatment of peripheral T-cell lymphoma, an uncommon but aggressive form of non-Hodgkin's lymphoma (NHL). (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 3, 2014 Category: Hematology Source Type: news

FDA Approves Belinostat for Rare LymphomaFDA Approves Belinostat for Rare Lymphoma
The new drug is for peripheral T-cell lymphoma, a rare and fast-growing type of non-Hodgkin's lymphoma. FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 3, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA approves Beleodaq to treat rare, aggressive form of non-Hodgkin lymphoma
The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency’s accelerated approval program. (Source: Food and Drug Administration)
Source: Food and Drug Administration - July 3, 2014 Category: American Health Source Type: news

Beleodaq Approved for Aggressive non-Hodgkin Lymphoma
When lymph nodes become cancerous (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 3, 2014 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

Lauryn Robinson loses battle with TWO rare forms of blood cancer
Eight-year-old Lauryn Robinson died at her home in Mold, North Wales, on Sunday, June 29, after a year-long battle with lymphoblastic leukaemia and Burkitts non-Hodgkins lymphoma. (Source: the Mail online | Health)
Source: the Mail online | Health - July 2, 2014 Category: Consumer Health News Source Type: news

Mayo Clinic Recommends New Routine Testing for some Non-Hodgkin Lymphomas
ROCHESTER, Minn. — A Mayo Clinic-led group of researchers has discovered three subgroups of a single type of non-Hodgkin lymphoma that have markedly different survival rates. These subgroups could not be differentiated by routine pathology but only with the aid of novel genetic tests, which the research team recommends giving to all patients with ALK-negative [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 26, 2014 Category: Databases & Libraries Source Type: news

Combination therapy may help patients with follicular lymphoma
(Rockefeller University Press) Follicular lymphoma is an incurable form of non-Hodgkin lymphoma that is diagnosed each year in 120,000 people worldwide. Researchers show that a high-risk group of patients with the disease could benefit from a novel drug combination. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 9, 2014 Category: Cancer & Oncology Source Type: news

Teena diagnosed with cancer after noticing trousers had become too tight
Emily Clark, 16, from South Wales, was diagnosed with non-Hodgkin lymphoma after becoming bloated and noticing two hard lumps in her abdomen. (Source: the Mail online | Health)
Source: the Mail online | Health - June 2, 2014 Category: Consumer Health News Source Type: news

'My favourite jeans saved my life': Teenager is diagnosed with cancer after noticing her trousers had suddenly become too tight
Emily Clark, 16, from South Wales, was diagnosed with non-Hodgkin lymphoma after becoming bloated and noticing two hard lumps in her abdomen. (Source: the Mail online | Health)
Source: the Mail online | Health - June 2, 2014 Category: Consumer Health News Source Type: news

Karyopharm Provides Data Update for Selinexor in Non-Hodgkin's Lymphoma and Acute Myeloid Leukemia at 2014 ASCO Annual Meeting
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - May 31, 2014 Category: Pharmaceuticals Source Type: news

Roche presents encouraging new data in common blood cancers for its investigational BCL-2 inhibitor GDC-0199/ABT-199 and polatuzumab vedotin, an anti-CD79b antibody drug conjugate
GDC-0199/ABT-199 combined with rituximab in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) shows encouraging activity. Head-to-head ROMULUS data in R/R non-Hodgkin lymphoma (NHL) support further development of polatuzumab vedotin (anti-CD79b ADC). (Source: Roche Investor Update)
Source: Roche Investor Update - May 31, 2014 Category: Pharmaceuticals Source Type: news

New drug for non-Hodgkin lymphoma, chronic lymphocytic leukemia passes early test
A new chemotherapy drug being investigated for its potency against two types of cancer was found by scientists to be effective in about one-third of the 58 patients who participated in a phase I study. The drug, alisertib or MLN8237, inhibits the enzyme aurora A kinase, which is known to be very active during cell division. The present study looks at the safety, tolerability, and preliminary success of alisertib in treating non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 23, 2014 Category: Science Source Type: news

New drug for non-Hodgkin lymphoma and chronic lymphocytic leukemia passes early test
(Houston Methodist) A new chemotherapy drug being investigated for its potency against two types of cancer was found by scientists at Houston Methodist and seven other institutions to be effective in about one-third of the 58 patients who participated in a phase I study. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 23, 2014 Category: Global & Universal Source Type: news

Hormone therapy linked to lower non-Hodgkin lymphoma risk
Menopausal hormone therapy use is linked to a lower risk of B-cell non-Hodgkin lymphoma, research has found. "The connection between lymphomas and menopausal hormone therapy use hinges on understanding the disease's biology and the window of susceptibility," the lead researcher said. "Hormone therapy is of interest because the loss of estrogen coupled with aging in women result in decreased immune function, which can elevate risk of non-Hodgkin lymphoma." (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 7, 2014 Category: Science Source Type: news

Roche's new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma
Roche announced today that the European Commission (EC) has approved a new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. (Source: Roche Media News)
Source: Roche Media News - March 28, 2014 Category: Pharmaceuticals Source Type: news

Roche's new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma
Roche announced today that the European Commission (EC) has approved a new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. (Source: Roche Investor Update)
Source: Roche Investor Update - March 28, 2014 Category: Pharmaceuticals Source Type: news

Hepatitis C Infection and Higher Risk of Death From Non-liver CancersHepatitis C Infection and Higher Risk of Death From Non-liver Cancers
In addition to their increased risk of death from hepatocellular carcinoma, chronic hepatitis C virus (HCV)-infected patients also have a higher mortality rate from non-Hodgkin lymphoma and pancreatic, rectal, and oral and pharyngeal cancers. Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 26, 2014 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

Scientists explore promising new option for first line of attack in lymphoma
(University of Manchester) A study led by Manchester scientists has shown promising results for a new treatment approach in follicular lymphoma. Follicular lymphoma is a type of non-Hodgkin's lymphoma -- a blood cancer -- that usually develops slowly. The majority of patients are diagnosed when their disease is at an advanced stage. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 25, 2014 Category: Cancer & Oncology Source Type: news

Cleveland Clinic Studies Radiation-induced Mesothelioma
James Stevenson, M.D., renowned oncologist at the Cleveland Clinic, didn't need to see the recent study to know the face of malignant pleural mesothelioma was changing. He sees it in his waiting room all the time. While occupational exposure to asbestos, which is still the No. 1 cause of the rare disease, continues dropping significantly, the rate of mesothelioma remains steady. And the patients don't look the same anymore. Other causes, it seems, are emerging, and they may be rising. "The general thinking is that these non-asbestos related cases will increase as we move forward," said Stevenson, a mesothelio...
Source: Asbestos and Mesothelioma News - February 12, 2014 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news